Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 76Neoplasm Metastasis 8Metastatic Castration Resistant Prostate Cancer 5Breast Neoplasms 5Neoplasms 3Metastatic Castration-Resistant Prostate Cancer 3Prostatic Neoplasms, Castration-Resistant 2Prostate Cancer Metastatic 2Castration-resistant Prostate Cancer 2Carcinoma, Non-Small-Cell Lung 2Salivary Glands Tumors 1Pharmacogenetic Study 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Newly Diagnosed Oligometastatic Prostate Cancer 1Metastatic Hormone Refractory Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-resistant Prostate Cancer 1Hyperaldosteronism 1Colorectal Neoplasms 1Advanced Cancer 1

Interventions

radium Ra 223 dichloride 1enzalutamide 1abiraterone 1Radium-223 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Metastatic Castration-resistant Prostate Cancer (mCRPC) × Abiraterone Acetate × Clear all
NCT04862091 2022-03-04

Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
69 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡